References
- Merola VM, Eubig PA. Toxicology of avermectins and milbemycins (macrocyclic lactones) and the role of P-glycoprotein in dogs and cats. Vet Clin North Am Small Anim Pract. 2018;48(6):991–1012.
- Omura S, Crump A. Ivermectin: panacea for resource-poor communities? Trends Parasitol. 2014;30(9):445–455.
- Wolstenholme AJ, Rogers AT. Glutamate-gated chloride channels and the mode of action of the avermectin/milbemycin anthelmintics. Parasitology. 2005;131:S85–S95.
- Crump A. Ivermectin: enigmatic multifaceted ‘wonder’ drug continues to surprise and exceed expectations. J Antibiot (Tokyo). 2017;70(5):495–505.
- Estrada-Mondragon A, Lynch JW. Functional characterization of ivermectin binding sites in α1β2γ2L GABA(A) receptors. Front Mol Neurosci. 2015;8:55.
- Ménez C, Sutra JF, Prichard R, et al. Relative neurotoxicity of ivermectin and moxidectin in Mdr1ab (-/-) mice and effects on mammalian GABA(A) channel activity. PLoS Negl Trop Dis. 2012;6(11):e1883.
- Guzzo CA, Furtek CI, Porras AG, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002;42(10):1122–1133.
- Krishna DR, Klotz U. Determination of ivermectin in human plasma by high-performance liquid chromatography. Arzneimittelforschung. 1993;43(5):609–611.
- González Canga A, Sahagún Prieto AM, Diez Liébana MJ, et al. The pharmacokinetics and interactions of ivermectin in humans-a mini-review. AAPS J. 2008;10(1):42–46.
- Klotz U, Ogbuokiri JE, Okonkwo PO. Ivermectin binds avidly to plasma proteins. Eur J Clin Pharmacol. 1990;39(6):607–608.
- Rendic SP. Metabolism and interactions of ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects. Arch Toxicol. 2021;95(5):1535–1546.
- Stromectol prescribing information. Whitehouse Station (NJ): Merck & Co.; 2009 [cited 2021 November 30]. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050742s024s025lbl.pdf
- Ndyomugyenyi R, Kabatereine N, Olsen A, et al. Efficacy of ivermectin and albendazole alone and in combination for treatment of soil-transmitted helminths in pregnancy and adverse events: a randomized open label controlled intervention trial in Masindi district, Western Uganda. Am J Trop Med Hyg. 2008;79(6):856–863.
- Nicolas P, Maia MF, Bassat Q, et al. Safety of oral ivermectin during pregnancy: a systematic review and Meta-analysis. Lancet Glob Health. 2020;8(1):e92–e100.
- Rodari P, Buonfrate D, Pomari E, et al. Ivermectin concentration in breastmilk of a woman with Strongyloides stercoralis and human T-lymphotropic virus-I co-infection. Acta Trop. 2020;202:105249.
- Ogbuokiri JE, Ozumba BC, Okonkwo PO. Ivermectin levels in human breastmilk. Eur J Clin Pharmacol. 1993;45(4):389–390.
- Durvet: ivermectin paste. Blue Springs (MO): Durvet Inc; 2021. [cited 30 November 21]. Available from https://www.durvet.com/wp-content/uploads/2017/12/ivermectin-paste_box_6.08g_0221_e.pdf
- Durvet: ivermectin injection for cattle & swine. Blue Springs (MO): Durvet Inc; 2021. [cited 2 July 22]. Available from https://www.durvet.com/wp-content/uploads/2017/09/ivermectin-inj_50mL_bimeda_0216.pdf
- Levy M, Martin L, Bursztejn AC, et al. Groupe de recherche de la société française de dermatologie pédiatrique. Ivermectin safety in infants and children under 15 kg treated for scabies: a multicentric observational study. Br J Dermatol. 2020;182(4):1003–1006.
- Kipp W, Bamhuhiiga J, Rubaale T, et al. Adverse reactions to ivermectin treatment in simulium neavei-transmitted onchocerciasis. Am J Trop Med Hyg. 2003;69(6):621–623.
- Matamoros G, Sánchez A, Gabrie JA, et al. Efficacy and safety of albendazole and high-dose ivermectin co-administration in school-aged children infected with Trichuris trichiura in Honduras: a randomized controlled trial. Clin Infect Dis. 2021;27:ciab365.
- Kamgno J, Gardon J, Gardon-Wendel N, et al. Adverse systemic reactions to treatment of onchocerciasis with ivermectin at normal and high doses given annually or three-monthly. Trans R Soc Trop Med Hyg. 2004;98(8):496–504.
- Smit MR, Ochomo EO, Aljayyoussi G, et al. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2018;18(6):615–626.
- Hall AH, Spoerke DG, Bronstein AC, et al. Human ivermectin exposure. J Emerg Med. 1985;3(3):217–219.
- Chung K, Yang CC, Wu ML, et al. Agricultural avermectins: an uncommon but potentially fatal cause of pesticide poisoning. Ann Emerg Med. 1999;34(1):51–57.
- Djeunga HN, Azafack CD, Thotchum FF, et al. Successful management of poisoning with ivermectin (mectizan) in the obala health district (Centre region, Cameroon): a case report. ASTMH. 2019;101(5):551.
- Edwards G. Ivermectin: does P-glycoprotein play a role in neurotoxicity? Filaria J. 2003;2(1):S8.
- Silva J, Khoja S, Asatryan L, et al. A novel pharmacotherapy approach using P-glycoprotein (PGP/ABCB1) efflux inhibitor combined with ivermectin to reduce alcohol drinking and preference in mice. Alcohology. 2020;86:1–8.
- Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003;42(1):59–98.
- Lin JH. How significant is the role of P-glycoprotein in drug absorption and brain uptake? Drugs Today (Barc). 2004;40(1):5–22.
- Yang CC. Acute human toxicity of macrocyclic lactones. Curr Pharm Biotechnol. 2012;13(6):999–1003.
- Baudou E, Lespine A, Durrieu G, et al. Serious ivermectin toxicity and human ABCB1 nonsense mutations. N Engl J Med. 2020;383(8):787–789.
- Macdonald N, Gledhill A. Potential impact of ABCB1 (P-glycoprotein) polymorphisms on avermectin toxicity in humans. Arch Toxicol. 2007;81(8):553–563.
- Wagstaff KM, Sivakumaran H, Heaton SM, et al. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J. 2012;443(3):851–856.
- Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
- FLCCC Alliance. I-MASK+ prevention and early outpatient treatment protocol for COVID-19 [Internet] (a). Washington (DC): FLCCC Alliance; c2020–2021. [cited 9.30.21]. Available from https://covid19criticalcare.com/wp-content/uploads/2020/11/FLCCC-Alliance-I-MASKplus-Protocol-ENGLISH.pdf
- FLCCC Alliance. I-RECOVER management protocol for long-haul COVID-19 syndrome (LHCS) [Internet] (b). Washington (DC): FLCCC Alliance; c2020–2021. [acc. [cited 9.30.21]. Available from https://covid19criticalcare.com/wp-content/uploads/2021/06/FLCCC-Alliance-I-RECOVER-Management-Protocol-for-Long-Haul-COVID-19-Syndrome.pdf
- FLCCC Alliance. MATH+ hospital treatment protocol for COVID-19 [Internet] (c). Washington (DC): FLCCC Alliance; c2020–2021. [cited 9.30.21]. Available from https://covid19criticalcare.com/wp-content/uploads/2021/01/FLCCC-Alliance-MATHplus-Protocol-ENGLISH.pdf.
- Rajter JC, Sherman MS, Fatteh N, et al. Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ivermectin in COVID nineteen study. Chest. 2021;159(1):85–92.
- Kory P, Meduri GU, Varon J, et al. Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. Am J Ther. 2021;28(3):e299–e318.
- Elgazzar A, Hany B, Youssef SA, et al. Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic. Res Square. 2020.
- Reardon S. Flawed ivermectin preprint highlights challenges of COVID drug studies. Nature. 2021;596(7871):173–174.
- Peña-Silva R, Duffull SB, Steer AC, et al. Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19. Br J Clin Pharmacol. 2021;87(3):1589–1590.
- Schmith VD, Zhou JJ, Lohmer LRL. The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19. Clin Pharmacol Ther. 2020;108(4):762–765.
- FDA. Why you should not use ivermectin to treat or prevent COVID-19 [Internet]. Silver Spring (MD): FDA; c2021. [cited 11.29.21]. Available from: https://www.fda.gov/consumers/consumer-updates/why-you-should-not-use-ivermectin-treat-or-prevent-covid-19
- Merck: merck statement on ivermectin use during the COVID-19 pandemic [Internet]. Kenilworth (NJ): Merck Sharpe & Dohne Corp; c2009–2021. [cited 11.30.21]. Available from: https://www.merck.com/news/merck-statement-on-ivermectin-use-during-the-covid-19-pandemic/.
- European Medicines Agency. EMA advises against use of ivermectin for the prevention of treatment of COVID-19 outside randomised clinical trials. Amsterdam (The Netherlands): European Medicines Agency; c2021. [cited 11.30.21]. Available from https://www.ema.europa.eu/en/news/ema-advises-against-use-ivermectin-prevention-treatment-covid-19-outside-randomised-clinical-trials
- NIH: COVID-19 treatment guidelines. Bethesda (MD): National Institutes of Health; c2021. [cited 11.30.21]. Available from https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ivermectin/
- World Health Organization. WHO advises that ivermectin only be used to treat COVID-19 within clinical trials [Internet]. Geneva, Switzerland: World Health Organization; c2021. [cited 11.30.21]. Available from: https://www.who.int/news-room/feature-stories/detail/who-advises-that-ivermectin-only-be-used-to-treat-covid-19-within-clinical-trials
- Calello DP, Kazzi Z, Stolbach A. American college of medical toxicology (ACMT) cautions against off-label prescribing of ivermectin for the prevention or treatment of COVID-19. J Med Toxicol. 2022;18(1):69–70.
- Lind JN, Lovegrove MC, Geller AI, et al. Increase in outpatient ivermectin dispensing in the US during the COVID-19 pandemic: a Cross-Sectional analysis. J Gen Intern Med. 2021;36(9):2909–2911.
- Temple C, Hoang R, Hendrickson RG. Toxic effects from ivermectin use associated with prevention and treatment of covid-19. N Engl J Med. 2021;385(23):2197–2198.